Lung-MAP: Biomarker-targeted second-line therapy in treating patients with recurrent stage IV squamous cell lung cancer.

Skip to Content

Clinical Trial Details

Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer

Lung-MAP: Biomarker-targeted second-line therapy in treating patients with recurrent stage IV squamous cell lung cancer.

Objective

Visit the National Cancer Institute's Web Site.

IRB Protocol Number
SWOG S1400 NCT 02154490

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000